News
BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO
BerGenBio to Participate in Investor Webcast and Q&A
BerGenBio ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates
BerGenBio ASA - Commencement of the subscription period for the rights issue
BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue
BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO
BGBIO – Ex. subscription rights today
BerGenBio ASA: Annual general meeting held
BerGenBio ASA – Updated key information relating to the preferential rights issue